Takeda Pharmaceutical Ltd ADR Down 8.10% To $13.33 After Earnings

Takeda Pharmaceutical Co Ltd (TAK) surpassed earnings projections on 10/26/2023 for Q2 2023.

The company reported an EPS of $0.48. The firm reported an EPS of $0.52 in the year-ago quarter. The decline in Takeda Pharmaceutical Ltd ADR's annual growth rate represents how the business isn't performing well amid current economic conditions.

Revenues were upbeat at $6.3 billion. That revenue figure represents a 12.65% decrease from the year ago quarter.

The stock is down 8.10% to $13.33 after the report.

Takeda Pharmaceutical Ltd ADR's revenues declined at a faster pace than earnings.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Takeda Pharmaceutical Ltd ADR has performed a little above average during the past few months. Before the report, Takeda Pharmaceutical Ltd ADR received a Long-Term Technical Rank by InvestorsObserver of 68, putting it in the top half of stocks. The firm set a 52-week high on April 6, 2023 at $17.15 and set a 52-week low on October 26, 2022 at $12.89.

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.